Need to take special care of non-responders to hepatitis B vaccination among health-care workers, students and chronic patients

References

• Sticchi L, Iavarone IG, Durando P, Di Biagio A, Schiavetti I, Murgia F, Icardi G The role of hepatitis B vaccine challenge dose in patients with underlying health conditions. Manuscript Number: KHVI-2020-0222.
   Google Scholar
• Grazzini M, Arcangeli G, Mucci N, Bonanni P, Bini C, Bechini A, Boccalini A, Tiscione E, Paolini D. High chance to overcome the non-responder status to hepatitis B vaccine after a further full vaccination course: results from the extended study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother. 2020;16(4):949–54. doi:10.1080/21645515.2019.1680082.
   PubMed Web of Science ®Google Scholar
• Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS, et al. Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med. 1986;105:356–60. doi:10.7326/0003-4819-105-3-356.
   PubMed Web of Science ®Google Scholar
• Sit D, Esen B, Atay A, Kayabasi H. Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy. World J Hepatol. 2015;7(5):761–68. doi:10.4254/wjh.v7.i5.761.
   PubMed Web of Science ®Google Scholar
• Said Z, Abdelwahab K. Induced immunity against hepatitis B virus. World J Hepatol. 2015;7(12):1660–70. doi:10.4254/wjh.v7.i12.1660.
   PubMed Web of Science ®Google Scholar
• Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med. 1989;321:708–12. doi:10.1056/NEJM198909143211103.
   PubMed Web of Science ®Google Scholar
• Clemens R, Sänger R, Kruppenbacher J, Hobel W, Stanbury W, Bock H, Jilg W. Booster immunization of low-and nonresponders after a standard three dose hepatitis B vaccine schedule— results of a post-marketing surveillance. Vaccine. 1997;15:349–52. PMID: 9141203. doi:10.1016/S0264-410X(96)00205-8.
   PubMed Web of Science ®Google Scholar
• Italian Ministry of Health. National immunization plan 2017-2019. Accessed 26 July 2020. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf
   Google Scholar
• Bonanni P, Chiamenti G, Conforti G, Maio T, Odone A, Russo R, Scotti S, Signorelli C, Villani A, Scientific Board of “Lifetime Immunization Schedule”. The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: a new paradigm to promote vaccination at all ages. Hum Vaccin Immunother. 2017;13(11):2531‐2537. doi:10.1080/21645515.2017.1366394.
   Web of Science ®Google Scholar
• Bonanni P, Azzari C, Castiglia P, Chiamenti G, Conforti G, Conversano M, Corsello G, Ferrera G, Ferro A, Icardi G, et al. The 2014 lifetime immunization schedule approved by the Italian scientific societies. Epidemiol Prev. 2014;38:131–46.
   PubMedGoogle Scholar
• Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P. Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother. 2018;14(2):450–55. doi:10.1080/21645515.2017.1398297.
   PubMed Web of Science ®Google Scholar
• Di Pasquale A, Bonanni P, Garçon N, Stanberry L, El-Hodhod M, Tavares Da Silva F. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016;34(52):6672–80. doi:10.1016/j.vaccine.2016.10.039.
   PubMed Web of Science ®Google Scholar
• Bechini A, Bonanni P, Lauri S, Tiscione E, Levi M, Prato R, Fortunato F, Martinelli D, Gasparini R, Panatto D. Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: the ESCULAPIO project. Hum Vaccin Immunother. 2017;13(2):369‐375. doi:10.1080/21645515.2017.1268008.
   Web of Science ®Google Scholar
• Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, Bonanni P. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother. 2013;9(5):1119‐1128. doi:10.4161/hv.23827.
   Web of Science ®Google Scholar
• Bonanni P, Pesavento G, Boccalini S, Bechini A. Perspectives of public health: present and foreseen impact of vaccination on the epidemiology of hepatitis B. J Hepatol. 2003;39(Suppl 1):S224‐S229. doi:10.1016/s0168-8278(03)00315-5.
   PubMedGoogle Scholar
• Zanella B, Bechini A, Boccalini S, Sartor G, Tiscione E, Bonanni P. Hepatitis B seroprevalence in the pediatric and adolescent population of Florence (Italy): an update 27 years after the implementation of universal vaccination. Vaccines (Basel). 2020;8(2):E156. Published 2020 Mar 30. doi:10.3390/vaccines8020156
   PubMed Web of Science ®Google Scholar
• Bonanni P. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine. 1995;13(S1):S68–S71. doi:10.1016/0264-410X(95)93553-L.
   PubMedGoogle Scholar
• Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Lo Nostro A. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine. 2003;21(7–8):685‐691. doi:10.1016/s0264-410x(02)00580-7.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M, Rapi S, Mercurio S, Mannelli F, Peruzzi M, et al. Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination. Hum Vaccin Immunother. 2013;9(3):636–41. PMID: 23354158. doi:10.4161/hv.23259.
   PubMed Web of Science ®Google Scholar